{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:21:54Z","timestamp":1775272914850,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science & Technology Development Fund of Tianjin Education Commission for Higher Education","award":["2021KJ204"],"award-info":[{"award-number":["2021KJ204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Open-label, prospective, multi-center phase II trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Three institutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Fifty-four patients scheduled to receive CapeOX chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants received GTDS (3.1\u00a0mg applied to the upper arm 48\u00a0h before chemotherapy, replaced on day 5, and discarded on day 12) and Dexamethasone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was the complete control rate of CINV. Secondary endpoints included the duration of delayed complete control, complete control rate in the acute phase, safety, and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The complete control rate for delayed CINV over the entire period (25\u2013480\u00a0h) was 72.7% (95% CI 0.57\u20130.88). The duration of delayed complete control was 17.2\u2009\u00b1\u20094.5 days, with 51.5% of patients experiencing no nausea during the delayed phase. The complete control rate in the acute phase was 81.8% (95% CI 0.69\u20130.95). No serious adverse events related to the antiemetic regimen were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prolonged administration of GTDS is safe and effective for preventing CINV in patients with gastrointestinal malignancies treated with CapeOX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov registry (NCT05325190); registered on October 10, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-024-12616-9","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:02:02Z","timestamp":1721314922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting"],"prefix":"10.1186","volume":"24","author":[{"given":"Cong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhansheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lining","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manman","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuchen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"23","key":"12616_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"1","key":"12616_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00520-019-05012-8","volume":"28","author":"RJ Wickham","year":"2020","unstructured":"Wickham RJ. Revisiting the physiology of nausea and vomiting-challenging the paradigm. SUPPORT CARE CANCER. 2020;28(1):13\u201321.","journal-title":"SUPPORT CARE CANCER"},{"key":"12616_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S80327","volume":"9","author":"K Kawakami","year":"2015","unstructured":"Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A, et al. Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence. 2015;9:561\u20137.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"12616_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/NNR.0b013e3182691438","volume":"61","author":"A Chan","year":"2012","unstructured":"Chan A, Tan SH, Low XH, Yap KY. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy. NURS RES. 2012;61(6):405\u201312.","journal-title":"NURS RES"},{"issue":"9","key":"12616_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3727\/096504017X15012905098071","volume":"25","author":"K Kawakami","year":"2017","unstructured":"Kawakami K, Yokokawa T, Kobayashi K, Sugisaki T, Suzuki K, Suenaga M, et al. Self-reported adherence to Capecitabine on Xelox Treatment as Adjuvant Therapy for Colorectal Cancer. Oncol Res 2017;25(9):1625\u201331.","journal-title":"Oncol Res"},{"issue":"1301\u20131302","key":"12616_CR6","first-page":"103","volume":"50","author":"A granisetron patch (sancuso)","year":"2008","unstructured":"A granisetron patch (sancuso). MED LETT DRUGS THER. 2008;50(1301\u20131302):103\u20134.","journal-title":"MED LETT DRUGS THER"},{"issue":"4","key":"12616_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.5056\/jnm15203","volume":"22","author":"D Midani","year":"2016","unstructured":"Midani D, Parkman HP. Granisetron Transdermal System for treatment of symptoms of gastroparesis: a prescription Registry Study. J Neurogastroenterol Motil. 2016;22(4):650\u20135.","journal-title":"J Neurogastroenterol Motil"},{"issue":"10","key":"12616_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00520-010-0990-y","volume":"19","author":"RV Boccia","year":"2011","unstructured":"Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. SUPPORT CARE CANCER. 2011;19(10):1609\u201317.","journal-title":"SUPPORT CARE CANCER"},{"issue":"8","key":"12616_CR9","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"AR Martin","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the functional living index-Emesis (FLIE) with 5-day recall. SUPPORT CARE CANCER. 2003;11(8):522\u20137.","journal-title":"SUPPORT CARE CANCER"},{"issue":"6","key":"12616_CR10","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00520-014-2507-6","volume":"23","author":"JE Kim","year":"2015","unstructured":"Kim JE, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, et al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. SUPPORT CARE CANCER. 2015;23(6):1769\u201377.","journal-title":"SUPPORT CARE CANCER"},{"issue":"6","key":"12616_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21037\/cco.2016.12.04","volume":"5","author":"LQ Yang","year":"2016","unstructured":"Yang LQ, Sun XC, Qin SK, Chen YX, Zhang HL, Cheng Y, et al. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Chin Clin Oncol. 2016;5(6):79.","journal-title":"Chin Clin Oncol"},{"key":"12616_CR12","unstructured":"Association of Physicians of India 52nd joint annual conference. APICON 97. Lucknow, January 11\u201315, 1997. Abstracts. J Assoc Physicians India. 1996;44(12):883\u20131011."},{"issue":"12","key":"12616_CR13","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1007\/s00520-020-05611-w","volume":"28","author":"AJ Chua","year":"2020","unstructured":"Chua AJ, Hernandez A, Real IO. Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis. SUPPORT CARE CANCER. 2020;28(12):5611\u20139.","journal-title":"SUPPORT CARE CANCER"},{"issue":"18","key":"12616_CR14","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.2165\/11202780-000000000-00000","volume":"69","author":"ST Duggan","year":"2009","unstructured":"Duggan ST, Curran MP. Transdermal granisetron. DRUGS. 2009;69(18):2597\u2013605.","journal-title":"DRUGS"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12616-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12616-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12616-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:02:55Z","timestamp":1721314975000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12616-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12616"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12616-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3265505\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the Tianjin Medical University Cancer Institute and Hospital in China approved the study (E20210665A). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"867"}}